This is a ready-to-use checklist for preparing the CMC and process-validation content of an FDA meeting briefing package, INTERACT, pre-IND, End-of-Phase 2, or pre-BLA, so the questions a reviewer would eventually raise in a BLA information request get raised and answered in the meeting instead. Replace every <<FILL: ...>> placeholder with your own specifics. A filled specimen follows.
Document control header
| Field | Entry |
|---|---|
| Document title | CMC / Validation Meeting Briefing Checklist for <<FILL: product / program>> |
| Meeting type | <<FILL: INTERACT / pre-IND / End-of-Phase 2 / pre-BLA>> |
| Meeting date (requested / confirmed) | <<FILL>> |
| Prepared by | <<FILL>> |
| Review date | <<FILL>> |
1. Purpose
This checklist confirms the CMC and validation content of a meeting briefing package states the program’s current thinking clearly enough for FDA to give a useful, specific reaction, rather than a package so vague or so exhaustive that the agency’s response cannot be applied to a real decision.
2. Scope
Applies to the CMC and process-validation sections of the briefing package for the meeting named above; does not cover the clinical, nonclinical, or regulatory-strategy sections, which follow their own preparation process in parallel.
3. Content checklist
| Item | Included? | Notes |
|---|---|---|
| Current manufacturing process description, at the level of detail appropriate to this meeting’s stage | <<FILL: Yes/No>> | <<FILL>> |
| Specific, answerable questions for FDA, not open-ended requests for general feedback | <<FILL>> | <<FILL>> |
| Intended process validation approach stated plainly: traditional, continuous, or hybrid | <<FILL>> | <<FILL>> |
| For an EOP2 or pre-BLA meeting: proposed PPQ batch count and its risk or statistical rationale | <<FILL>> | <<FILL>> |
| For an EOP2 or pre-BLA meeting: proposed comparability approach for any planned process or site change | <<FILL>> | <<FILL>> |
| Where a scaled-down model is used or planned, a clear statement of what it supports (characterization, parameter setting) versus what it does not (PPQ itself) | <<FILL>> | <<FILL>> |
| Any applicable expedited-program flexibility the program intends to rely on (RMAT CMC flexibility, a cell and gene therapy batch-count or lot-count flexibility guidance), named specifically rather than gestured at | <<FILL>> | <<FILL>> |
| Known open risks or gaps in the current validation strategy, stated honestly rather than omitted | <<FILL>> | <<FILL>> |
| Internal anticipated-questions review completed before the package is finalized | <<FILL>> | <<FILL>> |
4. Question quality review
| Draft question | Is it specific enough for a yes/no or a bounded answer? | Revised question |
|---|---|---|
<<FILL: e.g. "Is our approach to process validation acceptable?">> | <<FILL: No, too broad>> | <<FILL: e.g. "Does the Agency agree that a two-batch PPQ campaign, supported by the enhanced characterization program described in Attachment X, is sufficient given the limited number of qualified commercial-scale lots available for this product?">> |
A question FDA can only answer with “it depends” or “submit the data and we’ll review it” is a question that will not move the program forward; revise it until it asks for something specific and bounded enough to draw a real answer.
5. Disposition
| Field | Entry |
|---|---|
| Content checklist items outstanding | <<FILL>> |
| Questions revised for specificity | <<FILL>> |
| Recommendation | Package ready for internal sign-off / Hold pending the items above |
6. References
See the paired article, CMC Validation Summaries for Regulatory Filings, for how early meeting alignment connects to the validation content eventually written into S.2.5 and P.3.5. FDA, OTP INTERACT Meetings program description. FDA guidance on formal meetings between FDA and sponsors or applicants (Type A, B, and C meetings).
7. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
8. Approvals
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (CMC / Regulatory writer) | <<FILL>> | ||
| Approver (Regulatory Affairs Lead) | <<FILL>> |
Filled specimen
Extract for an illustrative RMAT-designated AAV gene therapy program preparing for its End-of-Phase 2 meeting.
| Item | Included? | Notes |
|---|---|---|
| Current manufacturing process description | Yes | Updated to reflect the process locked for pivotal-trial material, distinct from the earlier Phase 1 process description on file |
| Specific, answerable questions | Yes, after revision in section 4 | Original draft asked FDA to “confirm our validation plan is reasonable”; revised to three specific, bounded questions |
| Validation approach stated | Yes | Traditional process validation, three commercial-scale PPQ batches proposed |
| Batch count and rationale | Yes | Three batches proposed, tied to vector lot availability and the enhanced characterization program in the briefing package attachment |
| Comparability approach | Yes | Risk-based comparability plan for the planned scale-up from Phase 2 to commercial scale, attached as a summary table |
| Scaled-down model boundary | Yes | States plainly that scaled-down bioreactor data supports parameter-setting and viral clearance studies only, not the PPQ conclusion itself |
| Expedited-program flexibility named | Yes | RMAT designation named specifically; program states it is not relying on the 2026 CMC flexibility guidance’s single-lot method validation provision for this meeting’s questions |
| Known open risks stated honestly | Yes | States that long-term potency assay qualification is still in progress and will not be complete by BLA filing, with a proposed post-approval commitment |
| Anticipated-questions review completed | Yes | Internal review surfaced two questions FDA was likely to ask about the comparability plan; both incorporated into the briefing package narrative before submission |
Question quality review: the original draft question, “Is our approach to process validation acceptable?”, was revised to “Does the Agency agree that a three-batch PPQ campaign, using the enhanced characterization program described in Attachment 3, is sufficient to support licensure given the current vector lot production capacity described in Attachment 2?” The revised version gives FDA something specific to react to and gives the program a specific answer to carry into BLA drafting.
Common findings this checklist prevents
- A briefing package that asks FDA to “confirm our approach is acceptable” with no specific, bounded question behind it, drawing a response too general to act on.
- A validation strategy presented in the meeting that differs, even slightly, from what later appears in the BLA, because the meeting package and the filing were prepared by different people at different times with no reconciliation step.
- A known gap or risk omitted from the briefing package to avoid an uncomfortable question, surfacing instead as an unanticipated information request during formal review.
- An expedited-program flexibility referenced vaguely rather than named specifically, leaving FDA unable to react to the actual regulatory basis the program intends to rely on later.
How to adapt this checklist
- Scale section 3’s expectations to the meeting type; an INTERACT meeting’s content is necessarily less developed than a pre-BLA meeting’s, and this checklist should not force premature specificity onto an early-stage concept.
- Run every draft question through section 4 before the package is finalized; a specific question does more for the meeting’s outcome than any other element of the package.
- Cross-check the validation approach and batch-count rationale in this checklist against what PPQ readiness and prerequisites and the PPQ batch-count risk-based justification already establish, so the meeting package and the eventual protocol are not built independently of each other.
- After the meeting, reconcile the meeting minutes against this checklist and carry any FDA feedback forward into the eventual S.2.5 or P.3.5 draft explicitly, not from memory.